HLB Genex, Inc.
KKRX:1874202,270.00
KRW
-50.00
(-2.16%)
ISIN
KR7187420005
Return %
Stock
S&P 500
1Y
-27.59
14.39
3Y
-25.57
81.42
5Y
-75.35
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 82
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Daejeon South Korea
- IPO Date
- May 29, 2015
- Website
- genofocus.com
- Similar Companies
- Business
- HLB Genex, Inc. (formerly GenoFocus, Inc.) is a South Korea-based biotechnology company specializing in the research, engineering, and commercial manufacturing of specialty industrial enzymes, molecular diagnostic proteins, precision fermentation-derived bio-ingredients, and biopharmaceuticals. The company operates across multiple core segments, including Specialty Industrial Enzymes, Diagnostics & Life Sciences, Functional Bio-Materials, and Custom Enzyme & Biologics CDMO (Contract Development and Manufacturing Organization) Services. Its product portfolio includes industrial process enzymes, such as lactase for dairy processing and galacto-oligosaccharide (GOS) prebiotic production, catalase for hydrogen peroxide decomposition and surface cleaning in semiconductor, display, and textile manufacturing, and lipases for biocatalysis and specialty synthesis; molecular diagnostic and life science reagents, including recombinant Proteinase K, polymerases, and nucleic acid extraction enzymes utilized in polymerase chain reaction (PCR) kits and diagnostic assays; functional healthcare and cosmetic active ingredients, such as natural Vitamin K2 (Menaquinone-7), ceramides, and phytosphingosine produced via microbial precision fermentation; and therapeutic pipeline candidates utilizing enzyme engineering and microbial display platforms, including antioxidant superoxide dismutase (SOD) programs for age-related macular degeneration (AMD), non-alcoholic steatohepatitis (NASH), and inflammatory bowel disease (IBD). Additionally, the company offers proprietary directed evolution, microbial cell-surface display, custom expression optimization, and scale-up fermentation CDMO services to commercial partners across Asia, North America, and Europe. In late 2024, the company was acquired by the HLB Group through a multi-affiliate strategic investment valued at 80 billion won and subsequently rebranded from GenoFocus, Inc. to HLB Genex, Inc. to serve as the group's dedicated bio-manufacturing and enzyme development hub. Following this transaction, the company accelerated its strategic pivot toward high-margin biopharmaceutical and healthcare sectors, including expanding into central nervous system (CNS) therapeutic development through the acquisition of brain disease drug developer NeuroTobe. Founded in 2000 as a spin-off from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and listed on the KOSDAQ under ticker 187420, HLB Genex, Inc. is headquartered in Daejeon, South Korea, and operates specialized subsidiaries including GF Fermentech Co., Ltd.